Introduction {#s1}
============

Polymorphisms in the APEX nuclease (multifunctional DNA repair enzyme) 1 gene (*APEX1*) may be involved in the carcinogenesis by correcting DNA damage \[1\]. The *APEX1* encodes the major apurinic/apyrimidinic endonuclease in human cells, and the loss of bases in apurinic/apyrimidinic sites can usually block the progress of the DNA replication apparatus and cause mutations. Therefore, the genetic defects responsible for the repair capacity of the *APEX1* are often regarded as the logical candidates for its functional investigations. It is worth noting that a single transition of the 1349^th^ base pair T allele to G allele, inducing the substitution of the 148^th^ amino acid aspartate (Asp) to glutamate (Glu) (Asp148Glu, rs1130409), in the 5^th^ exon of the *APEX1*, has been extensively investigated in association with a wide range of cancers, such as lung cancer, breast cancer, and bladder cancer \[2-4\]. The results of individual association studies in the literature, however, are often controversial and inconclusive. Taking lung cancer as an example, the *APEX1* 148Glu allele was a risk-conferring factor in Caucasians \[5\], but a risk-reducing factor in Asians \[6\]. As a caveat, this lack of consistency might be attributable to the presence of genetic heterogeneity across ethnic populations, the insufficient sample sizes involved, and the possibly uncontrolled confounding effects. To shed some light on these issues and to generate more information, we sought to summarize available data on the association of the *APEX1* Asp148Glu polymorphism with all types of cancers from both English and Chinese literature via a meta-analysis, and further to explore the potential sources of between-study heterogeneity and the possible existence of publication bias.

Methods {#s2}
=======

Meta-analysis of observational studies poses particular challenges owing to its inherent biases and divergences in study design. We therefore carried out this meta-analysis according to the guidelines set forth by the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) statement \[7\] (Please see the [Checklist S1](#pone.0083527.s008){ref-type="supplementary-material"}).

Search strategy {#s2.1}
---------------

Four databases including the PubMed, EMBASE (Excerpta Medica database), Wanfang (<http://www.wanfangdata.com.cn>), and CNKI (China National Knowledge Infrastructure, <http://www.cnki.net>) were searched on May 1, 2013 for observational studies investigating the association between the *APEX1* Asp148Glu polymorphism and all types of cancers. Subject terms used for the search were: 'apurinic/apyrimidinic', 'APE1', '*APEX1*', 'cancer', 'tumor', 'neoplasm', combined with 'gene', 'polymorphism', 'variant', 'mutation', 'allele', or 'genotype'. The reference lists of all the retrieved articles as well as those of reviews on the same topic were also searched to identify the additional missing articles. Searching results were limited to studies with a case-control design and articles published in the English or Chinese language.

Study selection {#s2.2}
---------------

Two investigators (Dan Hu and Wenquan Niu) independently obtained the full texts of potentially eligible articles on the basis of their titles and abstracts. To avoid the double counting of the participants recruited in more than one publication, article authors were emailed for inquiry when necessary. In case of more than one publication from the same study population, the data from the most recent or the most complete publication were extracted.

Inclusion/exclusion criteria {#s2.3}
----------------------------

Our analyses were limited to the studies that strictly fulfilled the following inclusion criteria (all points must be satisfied for inclusion): (1) clinical endpoint (dependent variable): all types of cancers; (2) study design: either retrospective or nested case-control design; (3) independent variables: the genotype and/or allele counts of the *APEX1* Asp148Glu polymorphism. Studies were excluded (one point was sufficient for exclusion) if they investigated the progression, severity, phenotype modification, and the response to treatment or survival, as well as if they were conference abstracts, case reports or series, editorials, narrative reviews, and the non-English and non-Chinese articles.

Data extraction {#s2.4}
---------------

The data were extracted from all the qualified articles independently by two investigators (Dan Hu and Wenquan Niu) according to a standardized Excel template (Microsoft Corp, Redmond, WA). The discrepancies were resolved by the discussion and review of original articles, and a consensus was reached finally.

The data were collected on the first author, year of publication, ethnicity of the study population, cancer type, study design, case-control status, the genotypes/alleles of the *APEX1* Asp148Glu polymorphism between patients and controls, and the demographic data, if available, including age, gender, smoking, and drinking.

Quality score assessment {#s2.5}
------------------------

The study quality was evaluated by using a quality assessment score developed for genetic association studies by Thakkinstian and colleagues \[8\]. Total scores range from 0 (the worst) to 12 (the best). The criteria for quality assessment of genetic associations between the *APEX1* Asp148Glu polymorphism and cancer are described in the [Table S1](#pone.0083527.s001){ref-type="supplementary-material"}.

Statistical analyses {#s2.6}
--------------------

In this meta-analysis, four genetic models of inheritance were performed for *APEX1* Asp148Glu polymorphism including allelic model (the 148Glu allele versus the 148Asp allele), dominant model (the 148Glu/148Glu genotype plus the 148Glu/Asp genotype versus the 148Asp/Asp genotype), homozygous (the 148Glu/148Glu genotype versus the 148Asp/Asp genotype) and heterozygous (the 148Glu/Asp genotype versus the 148Asp/Asp genotype) genotypic models.

The random-effects model using the DerSimonian & Laird method was employed to compute the weighted odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs). Heterogeneity between studies was evaluated by the χ^2^ test, and was quantified by the inconsistency index (*I* ^2^) statistic, which ranges from 0% to 100% and is defined as the percentage of the observed between-study variability that is due to heterogeneity rather than chance.

Predefined subgroup analyses were performed a priori according to the cancer type, ethnicity of the study populations (Caucasian, Asian, African-American, or mixed), study design (population-based or hospital-based), the total sample size (\<300 subjects or ≥300 subjects), and the quality score (score \<7 or score ≥7). For a certain cancer, the data were presented and summarized if there were three or more independent studies that provided the genotype or allele counts of the Asp148Glu polymorphism between patients and controls.

Meta-regression analyses were performed to estimate the extent to which different study-level variables, including age, smoking, drinking, and quality score, explained the potential heterogeneity of pooled effect estimates of the *APEX1* Asp148Glu polymorphism on cancer risk.

Besides the Egger's test, publication bias was evaluated by the trim-and-fill method, which can estimate the number and outcomes of theoretically missing studies due to publication bias. P\<0.05 was considered statistical significance, except for the *I* ^2^ and Egger's statistics, for which significance was defined as P\<0.10 \[9\]. All statistical analyses were conducted by the STATA software (StataCorp, TX, version 11.2 for Windows).

Results {#s3}
=======

Eligible articles {#s3.1}
-----------------

A flow diagram schematizing the process of article selection with specific reasons is presented in [Figure 1](#pone-0083527-g001){ref-type="fig"}. In total, 413 potentially relevant articles were identified after the initial search, and 58 of them were deemed as eligible after applying further inclusion/exclusion criteria \[3-6,10-63\]. All qualified articles, including 52 articles written in English and 6 articles in Chinese \[39,48,51,52,55,57\], were published between the year 2003 and 2013. Because five articles provided data by ethnicity, two by cancer type, and two by the presence of menopause, there were 68 independent populations for comparisons in final analyses.

![Flow diagram of search strategy and study selection.](pone.0083527.g001){#pone-0083527-g001}

Study characteristics {#s3.2}
---------------------

The baseline characteristics of all qualified populations are shown in [Table 1](#pone-0083527-t001){ref-type="table"}, and the genotype distributions and allele frequencies of the *APEX1* Asp148Glu polymorphism between cancer patients and controls of all qualified populations are presented in the [Table S2](#pone.0083527.s002){ref-type="supplementary-material"}. Of 68 qualified populations, 14 were conducted for lung cancer, 10 for colorectal cancer, 9 for bladder cancer, 8 for breast cancer, 6 for prostate cancer, 4 for gastric cancer, 2 for pancreatic cancer, 2 for head and neck cancer, 2 for leukaemia cancer, and 1 for melanoma, biliary tract, cervical, esophageal, thyroid, hepatocellular, gioma, cervical, renal, endometrical carcinoma, and prostate cancers, respectively. The quality scores of all 68 populations ranged from 3 to 12, with a mean value of 6.9 (standard deviation: 1.92). Moreover, there were 30 populations involving Caucasians, 29 involving Asians, 4 involving African-Americans, and 5 involving the mixed populations. There were 27 populations conducted on a population-based design and 41 on a hospital-based design. 32 of 68 populations (47.1%) had the total sample size (the sum of patients and controls) equal to or greater than 300 participants in this meta-analysis.

10.1371/journal.pone.0083527.t001

###### The baseline characteristics of the study populations analyzed in this meta-analysis.

  **First author (year)**                       **Quality score**   **Cancer type**         **Ethnicity**       **Design**   **Sample size**   **Age (years)**           
  --------------------------------------------- ------------------- ----------------------- ------------------- ------------ ----------------- ----------------- ------- -------
  Misra RR et al (2003)                         5                   Lung                    Caucasian           Population   315               315               60      59
  Popanda O et al (2004)                        7                   Lung                    Caucasian           Hospital     463               460               61      55
  Ito H et al (2004)                            9                   Lung                    Asian               Hospital     178               449               62.9    62.6
  Chen L et al (2005)                           6                   Prostate                African-Americans   Population   124               116               64      59
  Chen L et al (2005)                           6                   Prostate                Caucasian           Population   228               219               64      62
  Shen M et al (2005)                           5                   Lung                    Asian               Population   119               113               55      55
  Broberg K et al (2005)                        6                   Bladder                 Caucasian           Population   63                158               69      69
  Zienolddiny S et al (2006)                    9                   Lung                    Caucasian           Population   343               413               65      60
  Zhang Y et al (2006) (Postmenopausal)         7                   Breast                  Caucasian           Population   839               679               NA      NA
  Zhang Y et al (2006) (Premenopausal)          7                   Breast                  Caucasian           Population   587               434               NA      NA
  Terry PD et al (2006)                         6                   Bladder                 Mixed               Hospital     239               215               65.7    63.3
  Moreno V et al (2006)                         10                  Colorectal              Caucasian           Hospital     359               312               NA      NA
  Li C et al (2006)                             6                   Melanoma                Caucasian           Hospital     602               603               NA      NA
  Li J et al (2006)                             6                   Pancreatic              Mixed               Hospital     384               357               NA      NA
  Li C et al (2007)                             6                   Head and neck           Caucasian           Hospital     830               854               NA      NA
  Huang M et al (2007)                          5                   Bladder                 Caucasian           Hospital     596               590               63.94   62.77
  Figueroa JD et al (2007)                      7                   Bladder                 Caucasian           Hospital     1150              1149              66      65
  De Ruyck K et al (2007)                       6                   Lung                    Caucasian           Hospital     110               110               62      61
  Berndt S et al (2007)                         11                  Colorectal              Mixed               Population   767               773               NA      NA
  Berndt S et al (2007)                         11                  Colorectal              Caucasian           Population   720               725               NA      NA
  Chang JS et al (2008)                         5                   Lung                    Mixed               Population   113               299               65.85   66.3
  Chang JS et al (2008)                         5                   Lung                    African-Americans   Population   255               280               63.51   61.81
  Zhu R et al (2008)                            5                   Leukaemia               Asian               Hospital     105               108               NA      NA
  Tse D et al (2008)                            8                   Esophageal              Caucasian           Hospital     312               454               64      64
  Smith TR et al (2008)                         7                   Breast                  Caucasian           Hospital     336               416               57.4    58.7
  Smith TR et al (2008)                         7                   Breast                  African-Americans   Hospital     63                78                57.4    58.7
  Shekari M et al (2008)                        6                   Cervical                Asian               Hospital     138               180               48.55   48.81
  Pardini B et al (2008)                        7                   Colorectal              Caucasian           Hospital     532               532               58.5    57.4
  Mitra AK et al (2008)                         5                   Breast                  Asian               Population   155               235               NA      NA
  Kasahara M et al (2008)                       6                   Colorectal              Asian               Hospital     68                121               67.3    67.4
  Huang WY et al (2008)                         7                   Biliary tract           Asian               Population   411               786               NA      NA
  Chiang FY et al (2008)                        7                   Thyroid                 Asian               Hospital     283               469               45.3    43.9
  Andrew AS et al (2008)                        8                   Bladder                 Caucasian           Hospital     1029              1281              NA      NA
  Sangrajrang S et al (2008) (Postmenopausal)   9                   Breast                  Asian               Hospital     239               180               48      45.3
  Sangrajrang S et al (2008) (Premenopausal)    9                   Breast                  Asian               Hospital     268               245               48      45.3
  Narter KF et al (2009)                        4                   Bladder                 Caucasian           Hospital     83                45                63.43   59.98
  Lu J et al (2009)                             9                   Lung                    Asian               Population   500               517               NA      NA
  Lo YL et al (2009)                            7                   Lung                    Asian               Hospital     730               730               60.77   60.8
  Liu Y et al (2009)                            7                   Glioma                  Caucasian           Population   373               365               NA      NA
  Gangwar R et al (2009)                        7                   Bladder                 Asian               Hospital     206               250               59      57.8
  Agachan B et al (2009)                        3                   Lung                    Caucasian           Hospital     98                67                51.26   48.81
  Ji L et al (2009)                             4                   Hepatocellular          Asian               Hospital     500               507               NA      NA
  Ye CC et al (2010)                            6                   Colorectal              Asian               Hospital     123               158               60.9    NA
  Wang M et al (2010)                           6                   Bladder                 Asian               Hospital     234               253               63.5    62.9
  Palli D et al (2010)                          9                   Gastric                 Caucasian           Population   314               548               68.8    55.5
  Osawa K et al (2010)                          6                   Lung                    Asian               Hospital     104               120               66.3    67.3
  Jelonek K et al (2010)                        5                   Colorectal              Caucasian           Hospital     103               153               NA      NA
  Jelonek K et al (2010)                        5                   Head and neck           Caucasian           Hospital     104               110               NA      NA
  Jelonek K et al (2010)                        5                   Breast                  Caucasian           Hospital     91                412               NA      NA
  Brevik A et al (2010)                         5                   Colorectal              Caucasian           Population   304               359               NA      NA
  Canbay E et al (2010)                         7                   Gastric                 Caucasian           Population   50                247               60.07   52.8
  Agalliu I et al (2010)                        9                   Prostate                Caucasian           Population   1308              1266              NA      NA
  Agalliu I et al (2010)                        9                   Prostate                African-Americans   Population   149               85                NA      NA
  Wang MM et al (2010)                          6                   Cervical                Asian               Hospital     306               306               46.84   46.04
  Huang LZ et al (2011)                         6                   Leukaemia               Asian               Hospital     415               519               NA      NA
  Li Z et al (2011)                             10                  Lung                    Asian               Hospital     455               443               59.68   58.39
  Kuasne H et al (2011)                         4                   Prostate                Mixed               Hospital     172               172               65.64   63.86
  Gu D et al (2011)                             7                   Gastric                 Asian               Hospital     338               362               61.76   62.46
  Cao Q et al (2011)                            6                   Renal                   Asian               Hospital     612               632               56.9    56.7
  Canbay E et al (2011)                         9                   Colorectal              Caucasian           Population   79                247               60.22   59.73
  Deng Q et al (2011)                           4                   Lung                    Asian               Population   315               315               59      58
  Zhonghua L et al (2011)                       5                   Gastric                 Asian               Hospital     126               156               58.7    53.1
  Nakao M et al (2012)                          9                   Pancreatic              Asian               Population   185               1465              NA      NA
  Mittal RD et al (2012)                        9                   Prostate                Asian               Population   195               250               66      64.7
  Mittal RD et al (2012)                        9                   Bladder                 Asian               Population   212               250               NA      NA
  Mandal R et al (2012)                         12                  Prostate                Asian               Population   192               224               62.6    59.1
  Cincin Z et al (2012)                         4                   Endometrial carcinoma   Caucasian           Hospital     104               158               56.2    53.71
  Li Y et al (2013)                             6                   Colorectal              Asian               Hospital     451               631               59.4    57

Abbreviations: NA, not available.

Overall analyses {#s3.3}
----------------

Analyses of the full data set indicated a marginally significant association of the *APEX1* Asp148Glu polymorphism with cancer risk under allelic (OR=1.05; 95% CI: 0.99-1.11; P=0.071), dominant (OR=1.09; 95% CI: 1.01-1.17; P=0.028), and heterozygous genotypic (OR=1.08; 95% CI: 1.01-1.16; P=0.026) models, with high probabilities of heterogeneity (*I* ^2^=70.6%, 67.1%, and 59.5% respectively, all P\<0.0005 from the χ^2^ test) ([Table 2 and Table 3](#pone-0083527-t002){ref-type="table"}). Moreover, the probability of publication bias was high as reflected by both the Egger's tests and the trim-and-ﬁll funnel plots for these three models ([Figure 2](#pone-0083527-g002){ref-type="fig"}). We estimated that there were respectively 10, 11, and 10 missing independent populations to make the funnel plots symmetrical under allelic, dominant, and heterozygous genotypic models.

10.1371/journal.pone.0083527.t002

###### Overall and subgroup estimates of the associations of *APEX1* Asp148Glu polymorphism with cancer risk under allelic and dominant models.

  **Groups/subgroups**    **Number of studies (cases/controls)**   **Allelic model**        **Dominant model**                                                       
  ----------------------- ---------------------------------------- ------------------------ -------------------- ------- ------------------------ ------------------ -------
  **Overall estimates**   68 (22398/26505)                         1.05; 0.99-1.11; 0.071   70.6% (\<0.0005)     0.049   1.09; 1.01-1.17; 0.028   67.1% (\<0.0005)   0.003
  **Cancer type**                                                                                                                                                    
  Lung cancer             14 (4007/4513)                           1.06; 0.95-1.19; 0.325   66.8% (\<0.0005)     0.018   1.1; 0.93-1.3; 0.268     67.6% (\<0.0005)   0.01
  Colorectal cancer       10 (3459/3978)                           1.07; 0.94-1.22; 0.325   72.2% (\<0.0005)     0.814   1.2; 0.97-1.49; 0.101    75.2% (\<0.0005)   0.681
  Bladder cancer          9 (3618/3918)                            0.99; 0.92-1.06; 0.701   3.4% (0.406)         0.481   0.99; 0.89-1.11; 0.903   10.4% (0.348)      0.058
  Breast cancer           8 (2546/2655)                            1.03; 0.88-1.21; 0.695   69.3% (0.002)        0.68    1.05; 0.82-1.34; 0.704   71.8% (0.001)      0.681
  Prostate cancer         6 (2122/2046)                            1.08; 0.98-1.2; 0.11     5.7% (0.38)          0.103   1.13; 0.95-1.35; 0.172   28.9% (0.218)      0.191
  Gastric cancer          4 (803/1311)                             1.42; 1.09-1.84; 0.009   71.0% (0.016)        0.16    1.74; 1.2-2.51; 0.003    64.9% (0.036)      0.082
  **Ethnicity**                                                                                                                                                      
  Caucasian               30 (12044/13249)                         1.06; 0.99-1.13; 0.116   66.5% (\<0.0005)     0.022   1.11; 1.0-1.24; 0.049    67.8% (\<0.0005)   0.011
  Asian                   29 (8161/10945)                          1.03; 0.64-1.14; 0.508   78.8% (\<0.0005)     0.617   1.05; 0.93-1.19; 0.438   71.6% (\<0.0005)   0.076
  African-American        4 (573/546)                              1.03; 0.86-1.22; 0.762   0.0% (0.578)         0.56    0.98; 0.77-1.25; 0.868   0.0% (0.507)       0.461
  Mixed                   5 (1620/1765)                            1.07; 0.92-1.23; 0.375   44.1% (0.128)        0.637   1.2; 0.95-1.53; 0.132    54.2% (0.068)      0.802
  **Study design**                                                                                                                                                   
  Population-based        27 (8984/11489)                          1.04; 0.97-1.11; 0.255   53.7% (0.001)        0.054   1.10; 0.99-1.22; 0.085   60.9% (\<0.0005)   0.035
  Hospital-based          41 (13414/15016)                         1.05; 0.98-1.14; 0.187   76.7% (\<0.0005)     0.25    1.08; 0.97-1.19; 0.148   70.8% (\<0.0005)   0.039
  **Sample size**                                                                                                                                                    
  ≥300 participants       32 (17084/18154)                         0.99; 0.94-1.04; 0.667   63.2% (\<0.0005)     0.071   0.99; 0.93-1.06; 0.834   50.2% (0.001)      0.509
  \<300 participants      36 (5314/8351)                           1.16; 1.05-1.3; 0.006    73.5% (\<0.0005)     0.016   1.26; 1.08-1.47; 0.003   73.1% (\<0.0005)   0.003
  **Quality score**                                                                                                                                                  
  ≥7                      34 (13846/16752)                         1.03; 0.98-1.08; 0.238   46.0% (0.0085)       0.202   1.06; 0.98-1.14; 0.152   49.1% (0.001)      0.061
  \<7                     (8477/9718)                              1.07; 0.97-1.19; 0.175   80.7% (\<0.0005)     0.143   1.13; 0.98-1.3; 0.099    76.8% (\<0.0005)   0.019

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.

10.1371/journal.pone.0083527.t003

###### Overall and subgroup estimates of the associations of *APEX1* Asp148Glu polymorphism with cancer risk under two genotypic models.

  **Groups/subgroups**    **Homozygous genotypic model**   **Heterozygous genotypic model**                                                       
  ----------------------- -------------------------------- ---------------------------------- ------- ------------------------ ------------------ -------
  **Overall estimates**   1.06; 0.96-1.17; 0.236           62.5% (\<0.0005)                   0.489   1.08; 1.01-1.16; 0.026   59.5% (\<0.0005)   0.002
  **Cancer type**                                                                                                                                 
  Lung cancer             1.07; 0.87-1.3; 0.537            54.9% (0.009)                      0.058   1.11; 0.93-1.32; 0.26    65.9% (\<0.0005)   0.008
  Colorectal cancer       1.03; 0.8-1.33; 0.815            65.1 % (0.005)                     0.158   1.25; 1.0-1.56; 0.055    74.7% (\<0.0005)   0.529
  Bladder cancer          0.94; 0.71-1.26; 0.686           56.5% (0.032)                      0.482   1.0; 0.9-1.11; 0.974     3.3% (0.404)       0.045
  Breast cancer           1.0; 0.78-1.27; 0.967            43.9% (0.086)                      0.687   1.05; 0.82-1.34; 0.697   67.9% (0.003)      0.703
  Prostate cancer         1.15; 0.95-1.4; 0.148            0.0% (0.705)                       0.001   1.1; 0.91-1.33; 0.591    29.4% (0.214)      0.271
  Gastric cancer          1.79; 1.11-2.89; 0.017           64.2% (0.039)                      0.332   1.66; 1.2-2.31; 0.002    50.7% (0.107)      0.054
  **Ethnicity**                                                                                                                                   
  Caucasian               1.06; 0.94-1.2; 0.332            54.5% (\<0.0005)                   0.213   1.11; 0.99-1.24; 0.063   65.1% (\<0.0005)   0.014
  Asian                   1.04; 0.85-1.27; 0.723           74.7% (\<0.0005)                   0.646   1.05; 0.94-1.17; 0.396   58.1% (\<0.0005)   0.033
  African-American        1.11; 0.77-1.61; 0.573           0.0% (0.71)                        0.533   0.94; 0.73-1.22; 0.646   0.0% (0.554)       0.421
  Mixed                   1.05; 0.81-1.36; 0.724           21.2% (0.28)                       0.708   1.24; 0.97-1.58; 0.083   52.1% (0.08)       0.83
  **Study design**                                                                                                                                
  Population-based        1.03; 0.92-1.16; 0.571           33.2% (0.052)                      0.151   1.12; 1.0-1.26; 0.051    63.2% (\<0.0005)   0.025
  Hospital-based          1.06; 0.92-1.23; 0.426           71.9% (\<0.0005)                   0.98    1.06; 0.97-1.16; 0.215   57.1% (\<0.0005)   0.043
  **Sample size**                                                                                                                                 
  ≥300 participants       1.21; 0.98-1.51; 0.082           64.6% (\<0.0005)                   0.164   1.23; 1.06-1.43; 0.006   69.1% (\<0.0005)   0.812
  \<300 participants      0.99; 0.9-1.09; 0.849            57.3% (\<0.0005)                   0.918   1.01; 0.95-1.07; 0.797   31.1% (0.05)       0.005
  **Quality score**                                                                                                                               
  ≥7                      1.05; 0.95-1.16; 0.317           43.5% (0.005)                      0.736   1.06; 0.98-1.15; 0.131   50.8% (\<0.0005)   0.056
  \<7                     1.08; 0.89-1.32; 0.433           73.6% (\<0.0005)                   0.536   1.12; 0.98-1.27; 0.087   66.6% (\<0.0005)   0.011

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval.

![Trim-and-ﬁll funnel plots for the effect of the *APEX1* Asp148Glu polymorphism on cancer risk under four genetic models.\
Hollow circles are the actual studies included in this meta-analysis, and solid squares are missing studies required to achieve symmetry.](pone.0083527.g002){#pone-0083527-g002}

Subgroup analyses {#s3.4}
-----------------

To account for the potential sources of between-study heterogeneity, a set of predefined subgroup analyses were conducted ([Table 2](#pone-0083527-t002){ref-type="table"}, [Table 3](#pone-0083527-t003){ref-type="table"}, and [Figures S1-S5](#pone.0083527.s003){ref-type="supplementary-material"}).

By cancer type, after the Bonferroni correction for the multiple testing (Bonferroni significance threshold P=0.05 divided by the number of cancers (n=6): P=0.0083), significant association was observed for gastric cancer under both dominant (OR=1.74; 95% CI: 1.2-2.51; P=0.003) and heterozygous genotypic (OR=1.66; 95% CI: 1.2-2.31; P=0.002) models, whereas no significance was reached for the other cancers under investigation. The heterogeneity between studies was relatively low for bladder and prostate cancers.

By ethnicity, the magnitude of risk estimates was marginally significant in Caucasians under both dominant (OR=1.11; 95% CI: 1.0-1.24; P=0.049) and heterozygous genotypic (OR=1.11; 95% CI: 0.99-1.24; P=0.063) models, whereas this significance failed to survive the stringent Bonferroni correction (Bonferroni significance threshold P=0.05 divided by the number of ethnicities (n=4): P=0.0125). In Asians and African-Americans, there was no significant association observed in this meta-analysis.

By study design, there were no significant differences in the pooled risk estimates between the population-based and hospital-based studies, with high probabilities of between-study heterogeneity and publication bias.

By sample size, the risk estimates were significantly overestimated in small studies (the total sample size \<300 participants), and no significance was reached in large studies (the total sample size ≥300 participants) under all but heterozygous genotypic model (OR=1.23; 95% CI: 1.06-1.43; P=0.006), even after the Bonferroni correction (Bonferroni significance threshold P=0.05 divided by the number of 2 groups: P=0.025). There was moderate evidence of heterogeneity.

By quality score, the risk estimates were relatively higher in low-quality studies (quality score \<7) than in high-quality studies (quality score ≥7), and there was no significance observed under all four genetic models. The presence of heterogeneity was more evident in low-quality studies than in high-quality studies. Significant publication bias was found under both dominant and heterozygous genotypic models.

Meta-regression analyses {#s3.5}
------------------------

To further explore additional sources of between-study heterogeneity, we constructed a multivariable meta-regression model that included age, smoking, drinking, and quality score as independent variables. However, none of these variables were observed to significantly affect the relationship between the *APEX1* Asp148Glu polymorphism and cancer susceptibility.

Discussion {#s4}
==========

Via a meta-analysis of the data from 58 articles and on 48903 participants, we investigated the association of the non-synonymous polymorphism Asp148Glu in *APEX1* with cancer risk. The principle finding of this study was that the *APEX1* 148Glu allele was associated with the significant risk of developing gastric cancer under both dominant and heterozygous genotypic models, even after the Bonferroni correction. Moreover, our subgroup analyses indicated that ethnicity might be an underlying cause of heterogeneity between studies. Although other sources of heterogeneity cannot be easily ruled out, this study, to the best of our knowledge, is so far the largest meta-analysis examining the association of the *APEX1* Asp148Glu polymorphism with cancer risk.

Recently, Zhou and colleagues have synthesized data from 32 case-control articles on the two polymorphisms of *APEX1*, and they failed to find any relationship between cancer risk and the Asp148Glu polymorphism \[64\]. By contrast, the findings of this meta-analysis supported the significant roles of the 148Glu allele in susceptibility to gastric cancer. However, a note of caution should be added because the risk estimates for gastric cancer were based on 803 patients and 1311 controls from 4 independent populations in this meta-analysis, the sample size might not be sufficient enough to derive a firm conclusion. It is recommended that to generate robust data, a much larger sample set encompassing more than 1000 participants in each group might be required \[65\]. A large, well-designed study is therefore warranted to confirm or refute the significance of our findings.

Moreover, extending the findings of the meta-analysis by Zhou and colleagues \[64\], we, in subgroup analyses, observed a marginally significant association of the *APEX1* Asp148Glu polymorphism with cancer risk in Caucasians under both dominant and heterozygous genotypic models, but not in Asians and African-Americans. One possible explanation for this divergence is the genetic heterogeneity across ethnicities. For example in this meta-analysis, the average frequency of the *APEX1* 148Glu allele was 34.82% in Asian controls, but was as exceedingly high as 45.21% in Caucasian controls. In general, genetic heterogeneity is an inevitable problem in any disease identification strategy. This ethnicity-specific effect suggests that different genetic backgrounds may account for this discrepancy or that different populations may have different linkage disequilibrium patterns due to the evolutionary history. As such, it is necessary to construct a database of susceptible genes and polymorphisms implicated in carcinogenesis in each ethnic group.

To seek additional sources of heterogeneity, an alternative method is to perform a meta-regression analysis; however, none of the confounders under study contributed remarkably to the presence of heterogeneity in this meta-analysis. It is important to bear in mind that meta-regression analysis, albeit enabling quantitative covariates to be considered, does not have the methodological rigor of a properly designed study that is intended to test the effect of these covariates formally. Admittedly, one limitation facing this method was the number of available studies with detailed information such as smoking and drinking. In fact, most studies did not report the study-level covariates of interest, precluding a more robust assessment of additional sources of heterogeneity.

Some limitations need to be acknowledged for this meta-analysis. First, all qualified studies were conducted on case-control design, which precludes further comments on a cause-effect relationship. Second, in both overall and subgroup analyses, most resultant associations might be biased by the moderate to high degree of between-study heterogeneity, which enhances the difficulty in drawing firm conclusions and encourages the exploration of other possible reasons for heterogeneity. Third, the overall findings of this study were skewed by publication bias, although publication bias was improved in most subgroups, possibly due to the lack of power for small number of studies involved. Factually as suggested by Hannah and colleagues, the study power is low if the number of studies included in a meta-analysis is 10 or fewer \[66\]. Moreover, potential selection bias cannot be completely ruled out, because we only retrieved studies from English and Chinese journals and published articles. Fourth, due to the relatively small sample sizes involved in subgroup analyses, we must hold some reservations about the interpretation of our subgroup results. Last but not the least, we only focused on the *APEX1* Asp148Glu polymorphism, and did not cover the other polymorphisms of *APEX1*. It is possible that the potential role of the examined polymorphism is diluted or masked by other gene-gene or gene-environment interactions. Thus, we cannot just to a conclusion until further confirmation of our findings has been undertaken.

In conclusion, via a meta-analysis of the data from 58 articles and on 48903 participants, we provide evidence that the *APEX1* Asp148Glu polymorphism might be a genetic risk factor for the development of gastric cancer. Nevertheless, despite the small sample sizes involved in subgroup analyses, this meta-analysis provides an anchoring point for better understanding of the pathogenesis of cancers. For practical reasons, we hope that this study will not remain just another endpoint of research instead of a beginning to establish the background data to understand the roles of the *APEX1* in carcinogenesis.
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